BusinessVaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s DiseaseBy Nasdaq OMXJan 30, 2018, 4:14 PM UTC
BusinessVaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface OncologyBy Nasdaq OMXJan 8, 2018, 6:10 PM UTC
BusinessVaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)By Nasdaq OMXOct 26, 2017, 2:23 PM UTC
BusinessVaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)By Nasdaq OMXApr 24, 2017, 2:28 PM UTC
BusinessVaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung CancerBy Nasdaq OMXOct 6, 2016, 1:45 PM UTC
BusinessVaccinex, Inc. Announces Continuation of the SIGNAL Clinical TrialBy Nasdaq OMXSep 9, 2016, 1:45 PM UTC
